# A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide

> **NCT00759824** · PHASE2 · COMPLETED · sponsor: **European Lung Cancer Working Party** · enrollment: 64 (actual)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Adriamycin, cyclophosphamide, vindesine, valproic acid

## Key facts

- **NCT ID:** NCT00759824
- **Lead sponsor:** European Lung Cancer Working Party
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2013-12
- **Final completion:** 2014-06
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2015-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00759824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00759824, "A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00759824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*